Skip to main content

Advertisement

SpringerLink
Log in

Antiretroviral treatment strategies in resource-limited settings

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

To date, a minority of persons living with HIV worldwide has benefited from the advances in HIV therapeutics fueled by the scientific community, policy-makers, advocates, and the pharmaceutical industry in the global North. A growing body of evidence demonstrates that access to highly active antiretroviral therapy can be successfully scaled-up in less wealthy nations in the South. High rates of adherence correspond with clinical, immunologic, and virologic outcomes similar to those seen in wealthier nations. Recent reports of successful programs highlight the provision of free care, reliance on the international funding sources, and proactive adherence counseling. As access to antiretroviral therapy has improved, there is an urgent need to develop better strategies for initiating and monitoring therapy, including the scale-up of viral load testing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Walensky RP, Paltiel AD, Losina E, et al.: The survival benefits of AIDS treatment in the United States. J Infect Dis 2006, 194:11–19.

    Article  PubMed  Google Scholar 

  2. Freedberg KA, Losina E, Weinstein MC, et al.: The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001, 344:824–831.

    Article  PubMed  CAS  Google Scholar 

  3. Joint United Nations Programme on HIV/AIDS, World Heath Organization: AIDS Epidemic Update: December 2006. http://www.unaids.org/en/HIV_data/epi2006/. Accessed January 31, 2007.

  4. Joint United Nations Programme on HIV/AIDS: 2006 Report on the Global AIDS Epidemic: Executive Summary. Geneva: World Health Organization; 2006:1–24.

    Google Scholar 

  5. Feachem RG, Sabot OJ: An examination of the Global Fund at 5 years. Lancet 2006, 368:537–540.

    Article  PubMed  Google Scholar 

  6. World Health Organization: Progress on Global Access to HIV Antiretroviral Therapy: A Report on “3 by 5” and Beyond. Geneva: World Health Organization; 2006.

    Google Scholar 

  7. Joint United Nations Programme on HIV/AIDS: Scaling Up HIV Access to Prevention, Treatment, Care, and Support: The Next Steps. Geneva: Joint United Nations Programme on HIV/AIDS; 2006:1–48.

    Google Scholar 

  8. Severe P, Leger P, Charles M, et al.: Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005, 353:2325–2334.

    Article  PubMed  CAS  Google Scholar 

  9. Goldie SJ, Yazdanpanah Y, Losina E, et al.: Cost-effectiveness of HIV treatment in resource-poor settings—the case of Cote d’Ivoire. N Engl J Med 2006, 355:1141–1153.

    Article  PubMed  CAS  Google Scholar 

  10. The World Bank: The World Bank Annual Report, 2003. http://www.worldbank.org/html/extpb/2003/download_report.html. Accessed February 16, 2007.

  11. Médecins Sans Frontières: Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries, edn 9. Geneva: Médecins Sans Frontières; 2006.

    Google Scholar 

  12. Weidle PJ, Wamai N, Solberg P, et al.: Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006, 368:1587–1594.

    Article  PubMed  Google Scholar 

  13. Bwire R: Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment. Trop Med Int Health 2006, 11:1567–1575.

    Article  PubMed  Google Scholar 

  14. Ferradini L, Jeanin, A, Pinoges, L, et al.: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006, 367:1335–1342.

    Article  PubMed  Google Scholar 

  15. Holmberg SD, Palella FJ Jr, Lichtenstein KA, Havlir DV: The case for earlier treatment of HIV infection. Clin Infect Dis 2004, 39:1699–1704.

    Article  PubMed  Google Scholar 

  16. Hammer S, Saag, M, Schechter, M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006, 296:827–843.

    Article  PubMed  CAS  Google Scholar 

  17. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-related Disease in Adults and Children. http://www.who.int/hiv/pub/guidelines/hivstaging/en/index.html. Accessed January 31, 2007.

  18. World Health Organization: Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-limited Settings: Toward Universal Access—Recommendations for a Public Health Approach. Geneva: World Health Organization; 2006.

    Google Scholar 

  19. World Health Organization: Scaling Up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach, 2003 revision. Geneva: World Health Organization; 2003.

    Google Scholar 

  20. Interim proposal for a WHO Staging System for HIV infection and disease. Wkly Epidemiol Rec 1990, 65:221–224.

  21. Stringer JS, Zulu I, Levy J, et al.: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006, 296:782–793.

    Article  PubMed  CAS  Google Scholar 

  22. Braitstein P, Brinkhof MW, Dabis F, et al.: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817–824.

    Article  PubMed  Google Scholar 

  23. Idigbe EO, Adewole TA, Eisen G, et al.: Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005, 40:65–69.

    Article  PubMed  CAS  Google Scholar 

  24. Danel C, Moh R, Minga A, et al.: CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006, 367:1981–1989.

    Article  PubMed  CAS  Google Scholar 

  25. Hakim J: A structured treatment interruption strategy of 12 week cycles on and off ART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomisation within the DART trial [abstract THLB0207]. Paper presented at the XVI International AIDS Conference. Toronto, Canada; August 13–18, 2006.

  26. Mills EJ, Nachega JB, Buchan I, et al.: Adherence to antiretroviral therapy in sub-Saharan Africa and North American: a mata-analysis. JAMA 2006, 296:679–690.

    Article  PubMed  CAS  Google Scholar 

  27. Nachega JB, Knowlton AR, Deluca A, et al.: Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults: a qualitative study. J Acquir Immune Defic Syndr 2006, 43(Suppl 1):S127–S133.

    PubMed  Google Scholar 

  28. Nachega JB, Stein DM, Lehman DA, et al.: Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses 2004, 20:1053–1056.

    Article  PubMed  CAS  Google Scholar 

  29. Crane JT, Kawuma A, Oyugi JH, et al.: The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS Behav 2006, 10:437–442.

    Article  PubMed  CAS  Google Scholar 

  30. Ramadhani H, Thielman N, Landman K, et al.: Predictors of maladherence among patients receiving fixed-dose combination stavudine/lamivudine/nevirapine in Northern Tanzania. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  31. Weiser S, Wolfe W, Bangsberg D, et al.: Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 2003, 34:281–288.

    Article  PubMed  Google Scholar 

  32. Laniece I, Ciss M, Desclaux A, et al.: Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003, 17(Suppl 3):S103–108.

    Article  PubMed  Google Scholar 

  33. Orrell C, Bangsberg DR, Badri M, Wood R: Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003, 17:1369–1375.

    Article  PubMed  Google Scholar 

  34. Gill CJ: Antiretroviral programme in rural Uganda. Lancet 2006, 368:1556–1557.

    Article  PubMed  Google Scholar 

  35. Calmy A, Ford N, Hirschel B, et al.: HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007, 44:128–134.

    Article  PubMed  Google Scholar 

  36. Bagchi S, Kempf MC, Westfall AO, et al.: Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis 2007, 44:135–138.

    Article  PubMed  CAS  Google Scholar 

  37. Schooley RT: Viral load testing in resource-limited settings. Clin Infect Dis 2007, 44:139–140.

    Article  PubMed  Google Scholar 

  38. Ramadhani H, Thielman N, Gao F, et al.: Predictors of virologic failure and HIV drug resistance among patients receiving fixed dose combination stavudine/lamivudine/nevirapine in northern Tanzania. Paper presented at the XVI International AIDS Conference. Toronto, Canada; August 13–18, 2006.

  39. Spacek LA, Shihab HM, Kamya MR, et al.: Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006, 42:252–259.

    Article  PubMed  Google Scholar 

  40. Coetzee D, Hildebrand K, Boulle A, et al.: Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004, 18:887–895.

    Article  PubMed  Google Scholar 

  41. Wester CW, Kim S, Bussmann H, et al.: Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005, 40:336–343.

    Article  PubMed  Google Scholar 

  42. DART Virology Group and Trial Team: Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006, 20:1391–1399.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases and International Health, Duke University Medical Center, Box 3152, Room 0371HS, Durham, NC, 27710, USA

    Nathan M. Thielman MD, MPH

Authors
  1. Anna K. Person MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Habib O. Ramadhani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nathan M. Thielman MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathan M. Thielman MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Person, A.K., Ramadhani, H.O. & Thielman, N.M. Antiretroviral treatment strategies in resource-limited settings. Curr HIV/AIDS Rep 4, 73–79 (2007). https://doi.org/10.1007/s11904-007-0011-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-007-0011-z

Keywords

Search

Navigation